Skip to main content

Table 1 Characteristics of study population by treatment strategies

From: Real-world outcomes of different treatment strategies in patients with diabetes and three-vessel coronary disease: a mean follow-up 6.3 years study from China

Variables PCI
(N = 1305)
CABG
(N = 899)
MT
(N = 913)
P value
Age (Years) 60.5 ± 10.1 61.3 ± 8.4 63.1 ± 9.8 < 0.001
Body mass index (kg/m2) 26.1 ± 2.9 25.9 ± 2.9 25.8 ± 3.1 0.163
Male 977 (74.9) 696 (77.4) 660 (72.3) 0.042
Hypertension history 943 (72.3) 632 (70.3) 643 (70.4) 0.514
Hyperlipidemia history 791 (60.6) 509 (56.6) 546 (59.8) 0.158
Chronic kidney disease history 7 (0.5) 15 (1.7) 19 (2.1) 0.004
COPD history 13 (1.0) 10 (1.1) 16 (1.8) 0.261
PAD history 64 (4.9) 121 (13.5) 106 (11.6) < 0.001
Smoking history 673 (51.6) 449 (49.9) 474 (51.9) 0.426
PCI history 180 (13.8) 88 (9.8) 126 (13.8) 0.842
CABG history 49 (3.8) 1 (0.1) 55 (6.0) 0.049
Revascularization history 307 (46.2) 130 (19.6) 227 (34.2) < 0.001
hsCRP (mg/L) 3.9 ± 6.1 3.8 ± 5.4 4.2 ± 4.8 0.455
Creatinine clearance (mL/min) 89.0 ± 28.5 86.8 ± 26.3 83.0 ± 28.2 < 0.001
LVEF 59.2 ± 8.8 57.8 ± 9.5 54.9 ± 11.7 < 0.001
SYNTAX score 22.2 ± 9.3 30.6 ± 9.2 26.3 ± 12.9 < 0.001
  1. Values are mean ± SD or n (%)
  2. PCI percutaneous coronary intervention, CABG coronary artery bypass grafting, MT medical treatment, COPD chronic obstructive pulmonary diseases, PVD peripheral vessel disease, hsCRP high-sensitivity C-reactive protein, LVEF left ventricular ejection fraction, SYNTAX Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery